Johnson & Johnson said Thursday that it had filed an application for emergency authorization of its coronavirus vaccine by the Food and Drug Administration.
The company’s vaccine has been hotly anticipated in part because it is administered as one dose, rather than the two-dose regimen seen with many other vaccines, and it can be stored in refrigerators.
Johnson and Johnson said in late January that the vaccine was 66 percent effective in a global study, with efficacy ranging as high as 72 percent in the U.S. and as low as 57 percent in South Africa, where a highly transmissible variant predominates.
The vaccine showed complete protection against hospitalization and death and 85 percent efficacy against severe disease.
View original post